Skip to main content
SpringerLink
Log in
Book cover

Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis

  • Book
  • © 2004

Overview

Editors:
  1. Otto R. Hommes

    1. European Charcot Foundation, Nijmegen, The Netherlands

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Giancarlo Comi

    1. Department of Neurology, Scientific Institute and University Ospedale San Raffaele, Milan, Italy

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Updates the reader on evolution in the MS field
  • New hypotheses and therapeutic options are presented

Part of the book series: Topics in Neuroscience (TOPNEURO)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (20 chapters)

  1. Front Matter

    Pages I-XV
    Download chapter PDF

  2. Evidence for an Early Treatment of Multiple Sclerosis

    • G. Comi, L. Moiola
    Pages 1-13

  3. Inflammation, Demyelination, and Axonal Degeneration: Three Aspects of the Pathogenesis of Multiple Sclerosis Revealed by Campath-1H Treatment

    • A. J. Coles, M. G. Wing, P. Molyneux, A. Paolillo, C. M. Davie, G. Hale et al.
    Pages 15-25

  4. Genetic Regulation of Nerve Cell Death/Glial Activation and Protective Effects of Myelin Basic Protein Autoimmune Neurotrophin Production in Mechanically Induced Neurodegeneration

    • F. Piehl, O. Lidman, T. Olsson
    Pages 27-39

  5. Neuroprotective Treatment in Primary Progressive Multiple Sclerosis: a Phase I/II Study with Riluzole

    • N. Kalkers, F. Barkhof, L. Bergers, R. Van Schijndel, C. Polman
    Pages 41-47

  6. Neuropathology and Disease Progression in Multiple Sclerosis

    • C. Bjartmar, B. D. Trapp
    Pages 49-61

  7. Autoimmune Inflammation and Multiple Sclerosis

    • I. R. Cohen
    Pages 63-66

  8. Early Treatment of Progression in Multiple Sclerosis

    • R. E. Gonsette
    Pages 67-81

  9. Imaging for Tissue Characterization in Multiple Sclerosis and Other White Matter Diseases

    • M. Filippi, N. De Stefano
    Pages 83-95

  10. Monounsaturated Fatty Acids and Neuroprotection. The Results of a Study of Cognitive Decline in Old Age. Is There a Case for this Treatment in Multiple Sclerosis?

    • A. Capurso, F. Panza, V. Solfrizzi, C. Capurso, A. D’Introno, S. Capurso et al.
    Pages 97-107

  11. Neuroprotection in Acute Ischemic Stroke: Lessons for Early Treatment in Multiple Sclerosis

    • J. De Keyser, G. Ramsaransing, E. Zeinstra, N. Wilczak
    Pages 109-114

  12. Soluble VCAM-1 Release Indicates Inflammatory Blood-Brain Barrier Pathology and Further Modulates Adhesion

    • B. A. Kallmann, V. Hummel, K. V. Toyka, P. Rieckmann
    Pages 115-117

  13. Early Treatment in Multiple Sclerosis with Intravenous Immunoglobulin: Rationale and Study Design

    • A. Achiron, Y. Barak, M. Faibel, S. Miron, I. Kishner, M. Chen et al.
    Pages 119-128

  14. Serial Magnetic Resonance Imaging in Patients with a First Clinical Episode Suggestive of Multiple Sclerosis: Outline of a Research Protocol

    • C. Pozzilli, P. Pantano, S. Di Legge, F. Caramia, M. C. Piattella, I. Pestalozza et al.
    Pages 129-133

  15. T1-Hypointense Lesions (T1 Black Holes) in Mild-to-Moderate Disability Relapsing Multiple Sclerosis

    • J. H. Simon, L. Jacobs, N. Simonian, The MS Collaborative Research Group
    Pages 135-139

  16. Acute Monosymptomatic Optic Neuritis: Potential Clues to Early Therapy in Multiple Sclerosis

    • D. I. Kaufman
    Pages 141-153

  17. Antibody Mediated Demyelination

    • A. Van Der Goes, E. C. W. Breij, M. Kortekaas, K. Hoekstra, P. J. H. Jongen, C. D. Dijkstra et al.
    Pages 155-161

  18. Anti-MOG Antibodies as Early Predictors for Conversion to Relapsing-Remitting Disease Course in Patients Suggestive of Multiple Sclerosis

    • T. Berger, P. Rubner, R. Egg, E. Dilitz, D. Stadlbauer, F. Deisenhammer et al.
    Pages 163-166

  19. Sunlight, Vitamin D, and Multiple Sclerosis

    • C. E. Hayes
    Pages 167-179

  20. The Yin and Yang of Inflammation in Multiple Sclerosis

    • G. Giovannoni
    Pages 181-189
Back to top

Keywords

About this book

There is now evidence that irreversible brain damage accumulates very early in the course of multiple sclerosis. This book reviews the main neurobiological, magnetic resonance imaging, and clinical aspects of the early phases of the dis­ ease. Mechanisms ofirreversible axonal damage and the role played by the inter­ action of glia and the axon are highlighted. In contrast to what was believed for a long time, the sufficient availability of oligodendrocyte precursor cells to promote remyelination in acute lesions has now been demonstrated. For reasons not understood, this remyelination process fails or does not start, particularly in the chronic stages ofthe disease. These findings emphasize the importance of the "milieu" changes induced by an inflammatory process in limiting remyelination. However, first indications are that part of this inflammatory process may have a neuroprotective effect. Pathological studies in multiple sclerosis have now clearly demonstrated that destructive processes may be followed by recovery phases in such a way that myelin may be morphologically and functionally reconstituted. These findings provide the rationale for early treatment and emphasize the importance of clinical trials in early multiple sclerosis. Early treatment is one of the most important aspects in multiple sclerosis today.

Editors and Affiliations

  • European Charcot Foundation, Nijmegen, The Netherlands

    Otto R. Hommes

  • Department of Neurology, Scientific Institute and University Ospedale San Raffaele, Milan, Italy

    Giancarlo Comi

Bibliographic Information

  • Book Title: Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis

  • Editors: Otto R. Hommes, Giancarlo Comi

  • Series Title: Topics in Neuroscience

  • DOI: https://doi.org/10.1007/978-88-470-2117-4

  • Publisher: Springer Milano

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Italia 2004

  • Hardcover ISBN: 978-88-470-0195-4Published: 06 February 2004

  • Softcover ISBN: 978-88-470-2171-6Published: 28 September 2012

  • eBook ISBN: 978-88-470-2117-4Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: XV, 199

  • Topics: Neurology, Neuroradiology

Publish with us

Policies and ethics

Back to top

Search

Navigation